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ABSTRACT
Background. Interleukin-2 (IL-2) antagonist has been used as an induction therapy in many centres in calcineurin inhibitor-
sparing regimens. Tacrolimus has overwhelmingly replaced cyclosporine in the maintenance immunosuppressive
protocols in many transplant centres. The aim of our study and meta-analysis is to explore the effect of IL-2 induction
therapy on the rate of rejection and patient and graft survival in standard-risk renal transplant patients with tacrolimus-
based maintenance immunotherapy. Secondary aims included assessment of the effect of IL-2 induction therapy on
creatinine change and the risk of cytomegalovirus (CMV) infection.
Methods. We conducted a systematic review in different databases to identify studies and research work that assessed the
effect of IL-2 antibody induction therapy on renal transplant outcomes. Inclusion criteria for our meta-analysis were all
studies that compared IL-2 induction therapy with placebo or no induction therapy in standard-risk renal transplant
recipients on tacrolimus-based maintenance immunosuppressive therapy. Data collected were the name of the first author,
journal title, year of publication, country where the study was conducted, number of patients in the IL-2 induction therapy
arm and in the placebo arm, number of patients who had biopsy-proven rejection and graft survival in each arm. A random
effects model was used for the meta-analysis.
Results. Of the 470 articles found in different databases, 7 were included in the meta-analysis. Forest plot analysis for rate of
rejection during the follow-up period post-transplant showed no significant difference between the groups. There was no
evidence of heterogenicity between included studies (I2¼21.8%, P¼0.27). The overall risk difference was 0.02 [95%
confidence interval (CI) 0.05–0.01]. A random effects meta-analysis for patient and graft survival was performed using
forest plot analysis and showed no significant effect of IL-2 receptor (IL-2R) antibody induction on patient or graft survival
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compared with placebo. The overall risk difference was 0.01 (95% CI 0.04–0.01) and 0.00 (95% CI 0.00–0.01), respectively.
Three of the included studies showed no effect of basiliximab on creatinine change, two showed no effect on risk of CMV
infection and two showed less risk of post-transplant diabetes in the basiliximab group.
Conclusion. IL-2R antibody induction therapy has no significant effect on the rate of rejection or patient or graft survival in
standard-risk renal transplant recipients on tacrolimus-based maintenance immunotherapy. More randomized controlled
studies are needed.
Keywords: basiliximab, daclizumab, rejection, renal transplantation, tacrolimus
INTRODUCTION
Outcomes of renal transplantation have improved significantly
over the last decade [1]. One of the main obstacles to better
transplant outcomes is the recurrent episodes of acute rejec-
tion, thus decreasing graft survival [2]. Many immunosuppres-
sive protocols have been designed aiming to overcome this
challenge [3]. Interleukin-2 receptor (IL-2R) antibody, a non-
depleting immunosuppressive agent, has been authorized for
induction therapy since 2000, with the aim of reducing the risk
of acute rejection and improving graft survival [4]. It is a mono-
clonal antibody agent that inhibits T-cell proliferation through
binding to IL-2 receptors on the T-helper cell surface [4].
Compared with T-cell depletive immunotherapy, IL-2 induction
therapy does not increase the risk of infection or risk of cancer
[5].
Many studies have proved that the use of IL-2R antibody as
induction therapy reduces the risk of acute rejection episodes in
renal transplant patients on cyclosporine-based maintenance
immunotherapy [6–8]. Furthermore, it has been used as an in-
duction therapy in many centres in calcineurin inhibitor–spar-
ing regimens [9–11]. In 2010, a meta-analysis included all
randomized controlled studies that assessed the outcome of IL-
2 induction therapy against placebo and those on T-cell deple-
tive induction therapy [12]. In this cohort, the renal transplant
recipients were principally at low immunological risk, with
more than one-third of the patients having no previous trans-
plants. This meta-analysis showed a lower risk of rejection in
IL-2R antibody induction compared with placebo. It also showed
no privilege of T-cell-depleting agents over IL-2R antibody in-
duction therapy. These results were one of the main reasons
that led the 2009 Kidney Disease: Improving Global Outcomes
(KDIGO) guidelines to recommend IL-2R antibody induction
therapy as part of routine immunosuppressive protocols [13]. In
most of the studies included in this meta-analysis, cyclosporine
was the main maintenance immunotherapy.
Tacrolimus has overwhelmingly replaced cyclosporine in
the maintenance immunosuppressive protocols in many trans-
plant centres [14]. This was based on many studies that showed
lower rejection rates in tacrolimus-based immunotherapy com-
pared with cyclosporine [15, 16]. The change to tacrolimus as a
maintenance immunotherapy may explain the significant de-
cline in the rate of rejection episodes from  50% 30 years ago to
 10% today [3, 16]. This raises the question of the significance
of IL-2R antibody induction therapy in the tacrolimus era and
whether it provides any benefits in decreasing the risk of
rejection, especially in standard-risk renal transplant patients.
The primary aim of our study and meta-analysis is to explore
the effect of IL-2R antibody induction therapy on the rate of
rejection and graft and patient survival in standard-risk renal
transplant patients on tacrolimus-based maintenance immuno-
therapy. Secondary aims included assessment of the effects of
IL-2 induction therapy on creatinine change, new-onset diabe-
tes post-transplant (NODAT) and risk of cytomegalovirus (CMV)
infection.
MATERIALS ANDMETHODS
Search strategy and inclusion criteria
We conducted a systematic review of the PubMed, MEDLINE,
Embase and Cochrane databases to identify studies and re-
search work that assessed the effect of IL-2 induction therapy
on renal transplant outcomes. The keywords used for this
search were basiliximab, daclizumab, interleukin-2, outcome,
rejection and graft survival. The literature search was per-
formed by two independent librarians and selected papers for
the meta-analysis were reviewed and accepted by all authors.
Manual searches were also conducted through references of rel-
evant and selected papers. Any conflicts among the results of
the literature search were reviewed and settled with a consen-
sus of all authors. Inclusion criteria for our meta-analysis were
all studies that compared IL-2 induction therapy with placebo
or no induction therapy in standard-risk renal transplant recipi-
ents. Studies excluded were studies with no control group, stud-
ies that compared IL-2 induction therapy with other depleting
or non-depleting antibodies, cyclosporine-based maintenance
immunotherapy, high-risk renal transplant recipients, follow-
up period <1 year, studies performed on animals, dual organ
transplant, organ transplant other than the kidneys, language
other than English, review articles and case reports and studies
that had similar cohorts to other larger studies.
Definitions and data extraction
Standard risk for renal transplant was defined as less than two
human leucocytic antigen DR (HLA-DR) mismatches, panel re-
active antibody (PRA) <20% and recipients with no more than
one previous transplant. This was based on the patient charac-
teristics in most of the papers included in this meta-analysis.
Data collected were name of the first author, journal title, year
of publication, country where the study was conducted, number
of patients in the IL-2R antibody induction arm and in the pla-
cebo arm, number of patients who had biopsy-proven or clinical
rejection and graft survival in each arm. Primary outcomes
were the number of acute rejection episodes and patient and
graft survival 1-year post-transplant. Secondary outcomes were
creatinine changes, new onset diabetes after transplant
(NODAT) and CMV infection. Ethical approval was not required
for the meta-analysis, as all studies included were already pub-
lished and available in different search engines.
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Statistical analysis and publication bias
Statistical analyses were done using Stata version 13
(StataCorp, College Station, TX, USA). The risk difference be-
tween both arms in the included studies was estimated from
the number of events in each arm. The risk difference was esti-
mated for the number of rejection episodes and for graft sur-
vival. A random effects model was used for the meta-analysis.
Heterogenicity among included studies for the effect sizes was
assessed using the DerSimonian method. P-values<0.1 were
the cut-off for heterogenicity. Forest plots were used to display
the results of the meta-analysis and the 95% confidence interval
(CI) was calculated for each study and displayed on the same
graph. Funnel and Galbraith plots were used to assess publica-
tion bias by estimating the effect size against standard error.
Two independent proportions analyses were used to compare
baseline categorical variables between the IL-2R antibody induc-
tion and no-induction group, while independent t-test analysis
was used for continuous variables.
RESULTS
A flow chart for the literature search is shown in Figure 1. Of the
470 articles found in different databases, 81 were repetitions;
389 were screened, of which 379 were excluded. Ten articles
were fully explored. Three of these were excluded due to the
short follow-up period. Seven articles were included in the
meta-analysis. These are shown in Tables 1 and 2 [17–23].
A total of 29 426 patients were included in the meta-analysis
(male 62.3% in the IL-2R antibody induction group and 62.9% in
the no-induction group). Baseline characteristics are shown in
Table 3. Diagnosis of acute rejection episodes was confirmed by
renal biopsy in all studies included in the meta-analysis except
for Wiland et al. [17], where this was not clearly mentioned.
There were no significant differences between baseline charac-
teristics of patients included in the IL-2R antibody induction
group and the no-induction group, as shown in Table 3.
Maintenance therapy in all studies included in the meta-
analysis was triple therapy [steroids, calcineurin inhibitor (CNI)
and mycophenolate or azathioprine].
Forest plot analysis for the rate of rejection during the
follow-up period post-transplant showed no significant differ-
ence between the groups, as shown in Figure 2 [risk difference
0.06 (95% CI 0.12–0.00)]. The highest weight in the forest plot
analysis was for the article by Gralla and Wiseman [18] [weight
24.09% (95% CI 0.02 to 0.01)] followed by Baek et al. [23]
[weight 17.81% (95% CI 0.06–0.08)]. There was evidence of het-
erogeneity between included studies (I2 ¼ 73.6%, P¼ 0.001). The
risk of bias was assessed using a Galbraith plot, as shown in
Supplementary data, Figure S3. Wiland et al. [17] was removed
from the forest plot analysis to eliminate the risk of heterogene-
ity, as shown in Figure 3 (I2¼ 21.8%, P¼ 0.27). The overall risk
difference was 0.02 (95% CI 0.05–0.01), indicating that IL-2R
antagonist has no influence on rejection rates. There was no ev-
idence of heterogeneity in the analysis (I2¼ 21.8%, P¼ 0.27).
There was no risk of bias after excluding the article by Wiland et
al. [17] using funnel plot and Galbraith plot analysis as shown in
Figure 4 and Supplementary data, Figure S6.
Random effects meta-analysis for graft survival was done us-
ing forest plot analysis and showed no significant effect of IL-2R
antibody induction on graft survival compared with placebo.
Forest plot analysis is shown in Figure 5. The greatest weight was
for the article by Gralla and Wiseman [18] [weight 97.34% (95% CI
0.00–0.01). There was no evidence of heterogenicity among
included studies (I2¼ 0.0%, P¼ 0.625). The risk of bias was
assessed using funnel plot analysis and a Galbraith plot as shown
in Figure 6 and Supplementary data, Figure S9, respectively.
Forest plot analysis for patient survival 1-year post-
transplant showed no significant different between both groups
as shown in Figure 7 [risk difference 0.01 (95% CI 0.04 – 0.01)].
The greatest weight was for the article by Gralla and Wiseman
[18] [weight 50.16% (95% CI0.03)] There was no evidence of
heterogenicity (I2 ¼ 41.5%, P¼ 0.145).
Only three articles compared changes in creatinine between
both groups. de Sandes-Freitas et al. [19] showed no difference in
renal function between both groups at the 1-year follow-up (cre-
atinine 1.49 mg/dL in the IL-2R antibody induction group, creati-
nine 1.47 mg/dL in the no-induction group). Gavela Martinez et al.
[22] and Baek et al. [23] showed similar results, with no difference
between the groups (P> 0.05). de Sandes-Freitas et al. [19] and
Baek et al. [23] were the only studies in our meta-analysis to as-
sess the risk of NODAT between the groups. Of the studies in-
cluded in the meta-analysis, Baek et al. [23] was the only one to
address the risk of CMV infection in transplant patients who re-
ceive IL-2R antibody as induction therapy. It found no significant
difference in the risk of CMV infection (2.8% in the IL-2R antibody
induction group and 0% in the no-induction group).
DISCUSSION
In this meta-analysis, seven studies were included for assess-
ment of risk of acute rejection in the standard-risk populationFIGURE 1: Flow chart for the literature search.
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Table 1. Papers included in the meta-analysis
Reference Type of study Country Journal Year
Wiland et al. [17] Retrospective observational study USA Transplantation 2004
Gralla and Wiseman [20] Retrospective observational study USA Transplantation 2010
de Sandes-Freitas et al. [19] Retrospective observational study Brazil International Urology and Nephrology 2013
Schwarz et al. [20] Retrospective observational study Austria Transplantation Proceedings 2015
Umber et al. [21] Retrospective observational study Italy Journal of Nephrology 2017
Gavela Martinez et al. [22] Retrospective observational study Spain Transplantation Proceedings 2009
Baek et al. [23] Prospective study Korea Experimental and Clinical Transplantation 2016
Table 2. Baseline characteristics for papers included in the meta-analysis
References
Follow-up
period,
years
Patients
on IL-2R antibody
induction, n Rejections, n
Graft
survival
(no. of
patients) Deaths, n
Patients
not on
induction, n Rejections, n
Graft
survival
(no. of
patients) Deaths, n
Wiland et al. [17] 1 126 5 119 136 29 129
Gralla and Wiseman [18] 1 14 482 1676 13 859 377 14 204 1843 13 607 355
de Sandes-Freitas et al. [19] 1 134 23 118 8 132 21 113 7
Schwarz et al. [20] 1 83 20 65 27
Umber et al. [21] 1 56 11 54 2 58 16 52 1
Gavela Martinez et al. [22] 1 21 2 19 1 36 6 35 1
Baek et al. [23] 1 72 3 72 0 36 1 36 0
Table 3. Comparison of baseline characteristics of IL-2R antibody induction group and no-induction group
Baseline characteristics
IL-2R
antibody induction
group (n¼ 14 974)
No-induction
group (n¼ 14 667) P-value
Male (%) 62.3 62.9 0.28
Recipient mean age (years) 48.65 47.09 P-value cannot be obtained as
raw data are not available
Donor mean age (years) 40.05 38.95 P-value cannot be obtained as raw data are not available
Mean cold ischaemia time (h) 19.3 16.1 P-value cannot be obtained as raw data are not available
Extended criteria donors, n 1347 1388 0.16
FIGURE 2: Forest plot analysis for risk of rejection 1-year post-transplant.
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FIGURE 3: Forest plot analysis for risk of rejection 1-year post-transplant after excluding Wiland et al. [18].
FIGURE 4: Funnel plot for random effects meta-analysis for risk of rejection after excluding Wiland et al. [18].
FIGURE 5: Forest plot analysis for graft survival 1-year post-transplant.
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with IL-2R antibody induction versus placebo, five of them were
used in the meta-analysis for graft survival 1-year post-
transplant. To our knowledge, this is the first meta-analysis to
be conducted on this topic in the tacrolimus era.
Formerly, Webster et al. [12] conducted a large meta-analysis
that included primarily studies with cyclosporine-based main-
tenance immunosuppression. Authors of this meta-analysis
reported a decrease in the risk of acute rejection of 28% in those
receiving IL-2R antibody induction therapies, with a relative risk
of 0.72. Based on these results, they concluded that for every
100 renal transplant recipients receiving IL-2R antibody induc-
tion therapy, the risk of acute rejection episodes would be
expected to decrease by 14 patients. They also concluded that
the number needed to treat to prevent one rejection event was
seven patients. The KDIGO guidelines, based on results of this
meta-analysis, recommend IL-2R antibody induction as stan-
dard induction therapy in low-risk renal transplant patients
[13]. However, since many centres today use tacrolimus as
maintenance immunotherapy, questions about the validity of
the results of this meta-analysis were raised.
Many studies have compared long-term outcomes of renal
transplant using cyclosporine and tacrolimus as maintenance
immunotherapy. The Symphony study showed better graft sur-
vival and less risk of acute rejection events at 1-year follow-up
post-transplant in patients receiving tacrolimus compared with
those receiving cyclosporine [16]. Furthermore, a long-term
multicentre European study found similar results when they
followed-up the patients for 5 years post-transplant [24]. In
2002, Vincenti et al. [25] showed similar results in a multicentre
trial in the USA with a follow-up period of 5 years after trans-
plant. The favourable long-term outcome for patients using
tacrolimus as maintenance therapy compared with cyclospor-
ine could be due to a less nephrotoxic effect of the former com-
pared with the latter [26]. It could also be related to the more
powerful immunosuppressive effect of tacrolimus compared
with cyclosporine, ending in a lower rate of chronic rejection.
The better outcomes of patients on tacrolimus maintenance
therapy and fewer nephrotoxic effects raised concerns about
the need and the benefit of induction therapy in the standard-
risk population. Our meta-analysis showed no additional
FIGURE 6: Funnel plot for random effects meta-analysis for graft survival post-transplant.
FIGURE 7: Forest plot analysis for patient survival 1-year post-transplant.
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benefit of IL-2R antibody induction therapy in standard-risk
patients in the tacrolimus era.
In previous studies there were conflicting data about the ac-
tual benefit of IL-2R antibody induction therapy in the stan-
dard-risk population. Willoughby et al. [27], using a composite
endpoint of acute rejection and graft loss or death, found
favourable outcomes for those having IL-2R antibody induction
therapy versus placebo (tacrolimus and mycophenolate mofetil
were the drugs used for maintenance immunotherapy). On the
other hand, Lim et al. [28], on analysing data from the
Australian registry database, did not find any significant de-
crease in the risk of rejection when using IL-2R antibody
induction therapy in the low- or intermediate-risk population
(cyclosporine and tacrolimus were the CNIs used in the study
for maintenance immunotherapy). Both of these studies were
not included in our meta-analysis due to the short follow-up pe-
riod (6 months). Similarly, in 2015, Tanriover et al. [29] proved in
a large study using data from the Organ Procurement and
Transplantation Network (OPTN) registry that there is no addi-
tional benefit from using IL-2R antibody induction therapy in
transplants from living donors. This study was also excluded
from our meta-analysis, as almost half of the included patients
were high-risk transplants with PRA> 20% and also because of
overlap between data included in this study and that used in
Gralla and Wiseman [18]. In 2016, Tanriover et al. [30] repeated
the same study using OPTN data on transplants from deceased
donors. The study showed no additional benefit from using IL-
2R antibody induction therapy in transplants from deceased
donors. Most of the included patients in this study did not meet
our criteria defining a standard-risk population (PRA< 20%, no
more than two transplants, DR mismatch <2). Subgroup analy-
sis of low-risk transplants showed no effect of IL-2 induction
therapy on rejection rates or survival; however, details of this
group were not thoroughly discussed in the study. Also, there
was overlap of the data in this study with that of Gralla and
Wiseman [18] and therefore it was not included in our meta-
analysis.
Our analysis showed a possible degree of heterogeneity
among included studies when assessing the risk of acute rejec-
tion, while the studies were homogeneous when assessing graft
survival. This could be due to variations in the definition of a
standard-risk population among different studies and centres.
The stratification of immunological risk depends on several fac-
tors related to the recipient and the characteristics of the donor.
The risk factors for acute rejection included the age of the recip-
ient and donor, degree of HLA mismatch, cold ischaemia time,
ethnicity, PRA, presence of donor-specific antibodies, blood
group incompatibility and previous failed transplants [13]. In
the UK, guidelines to standardize definitions of high and low
immunological risk populations are under development [31]. On
repeat analysis after eliminating the risk of heterogenicity,
again IL-2 induction therapy did not show any benefit in de-
creasing the risk of rejection.
The strengths of our study are the inclusion of several stud-
ies from different countries and thereby being less influenced
by local findings compared with single-country studies and gen-
eralization of the population of studies, thus having higher sta-
tistical power to detect an effect. Limitations include several
points. The follow-up period of 1 year is too short to draw defini-
tive conclusions on graft survival. All we know is that 12 months
is not always enough time to evaluate the damage of a previous
acute rejection. The percentage of extended criteria donors in
our analysis is low compared to the current set-up in clinical
transplantation which is around 20–60% of deceased donor
grafts [32]. One cannot exclude that, in particular, this type of
graft may benefit from IL-2R antibody induction use in order to
spare CNIs.
In conclusion, IL-2R antibody induction therapy has no
significant effect on the rate of rejection and patient or graft
survival in standard-risk renal transplant recipients on
tacrolimus-based maintenance immunotherapy.
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